Anibal Chertcoff, MD, PhD, The University of British Columbia, Vancouver, Canada, provides an overview of future research on polypharmacy and multiple sclerosis (MS). While past studies have explored hospitalizations as a complementary analysis, it would be of great interest to examine other outcomes, such as mortality and visits to the emergency department due to adverse effects of drug interactions. Additionally, studying polypharmacy in different populations, including older adults and individuals with comorbidities. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Award from MS Society of Canada and Michael Smith Foundation.